Table 1 Characteristics at diagnosis and follow-up for patients (N = 279), split by treatment group. Median values and range are reported for the groups

N

61

34 (32^c)

115

69

Age at diagnosis (years)

30 (18–52)

30 (16–49)

27 (16–47)

28 (18–52)

0.09

< 0.001

Age at sample collection (years)

48 (29–64)

45 (28–74)

44 (23–61)

43 (26–62)

0.81

< 0.001

Age at survey II (years)

51 (36–69)

52 (36–68)

47 (31–66)

48 (33–68)

0.06

< 0.001

Time between surgery and sample collection (years)

17 (5–27)

18 (6–35)

17 (6–28)

14 (5–28)

0.02

0.02

Time between sample collection and MetS diagnosis (years)

0 (0–9)

8 (− 8–9)

0 (0–9)

8 (0–9)

<0.001

0.09

Initial disease stage

< 0.001

0.58

I

18

32

35

66

IMK positive^d/II

36

0

58

3^e

III

2

0

4

0

IV

5

0

18

0

Histology

0.16

0.15

Seminoma

8

1

6

2

Non-seminoma

53

31

109

67

Cumulative cisplatin dose (mg)

790 (570–920)

760 (495–1400)

< 0.001

Testosterone (nmol/L)^f

11.1 (3–26)

12 (3–24)

15 (3–32)

16 (6–38)

0.30

< 0.001

Physical activity

0.40

0.002

Very active

26

12

72

36

Moderate

25

16

37

28

Sedentary

10

4

5

4

Smoking status

0.77

0.13

Never smoker (%)

43

33

51

49

Former smoker (%)

34

42

24

28

Current smoker (%)

23

24

24

23

Mean β methylation

0.62

0.62

0.62

0.62

0.21

0.71